- Home
- PACS vs CGON Comparison
PACS vs CGON Comparison
Compare PACS & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PACS
- CGON
- Stock Information
- Founded
- PACS 2013
- CGON 2010
- Country
- PACS United States
- CGON United States
- Employees
- PACS N/A
- CGON N/A
- Industry
- PACS
- CGON
- Sector
- PACS
- CGON
- Exchange
- PACS Nasdaq
- CGON NYSE
- Market Cap
- PACS 1.5B
- CGON 1.3B
- IPO Year
- PACS 2024
- CGON 2024
- Fundamental
- Price
- PACS $9.82
- CGON $26.26
- Analyst Decision
- PACS Strong Buy
- CGON Strong Buy
- Analyst Count
- PACS 7
- CGON 10
- Target Price
- PACS $34.29
- CGON $64.00
- AVG Volume (30 Days)
- PACS 425.7K
- CGON 1.4M
- Earning Date
- PACS 06-10-2025
- CGON 05-13-2025
- Dividend Yield
- PACS N/A
- CGON N/A
- EPS Growth
- PACS 82.80
- CGON N/A
- EPS
- PACS 0.68
- CGON N/A
- Revenue
- PACS $3,558,953,000.00
- CGON $662,000.00
- Revenue This Year
- PACS $29.74
- CGON N/A
- Revenue Next Year
- PACS $14.22
- CGON $12,387.03
- P/E Ratio
- PACS $14.50
- CGON N/A
- Revenue Growth
- PACS 205.08
- CGON 224.51
- 52 Week Low
- PACS $8.28
- CGON $14.80
- 52 Week High
- PACS $43.92
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- PACS N/A
- CGON 56.19
- Support Level
- PACS N/A
- CGON $24.95
- Resistance Level
- PACS N/A
- CGON $26.60
- Average True Range (ATR)
- PACS 0.00
- CGON 1.41
- MACD
- PACS 0.00
- CGON 0.01
- Stochastic Oscillator
- PACS 0.00
- CGON 64.14
About PACS PACS Group Inc. Common Stock
PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.